Evidence map›Paper›PMID 40089775›Full record

ArticleEuropean journal of medical research2025

Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan.

Kuan-Chieh Tu, Wei-Ting Chang, Hui-Wen Lin, Po-Lin Lin, Yen-Wen Wu, Chao-Feng Lin, Hung-I Yeh, Min-Ji Charng, Po-Hsun Huang, Tsung-Hsien Lin and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kuan-Chieh Tu *Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Wei-Ting Chang *Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Hui-Wen LinDepartment of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Po-Lin LinCardiovascular Center, Department of Medical Research, MacKay Memorial Hospital and Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
Yen-Wen WuDivision of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Chao-Feng LinCardiovascular Center, Department of Medical Research, MacKay Memorial Hospital and Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
Hung-I YehCardiovascular Center, Department of Medical Research, MacKay Memorial Hospital and Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
Min-Ji CharngDivision of Cardiology, Department of Medicine, Taipei Veterans General Hospital, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Po-Hsun HuangDivision of Cardiology, Department of Medicine, Taipei Veterans General Hospital, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Tsung-Hsien LinDivision of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Wei-Wen LinCardiovascular Center, Taichung Veterans General Hospital, Department of Life Science, Tunghai University, Taichung, Taiwan.
I-Chang HsiehDivision of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
Feng-Yu KuoDivision of Cardiology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Ching-Pei ChenDivision of Cardiology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
Sheng-Hsiang LinDepartment of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yi-Heng LiDepartment of Internal Medicine, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, 138 Sheng Li Road, Tainan, Taiwan. heng@mail.ncku.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveProprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a standard therapy for patients who respond poorly to or cannot tolerate statins. However, identifying responders to PCSK9 inhibitors remains unclear. This study investigates the characteristics of patients who achieve target LDL-C reduction (< 70 mg/dl) after PCSK9 inhibitor therapy.

methodsA multicenter, retrospective cohort study included patients initiating PCSK9 inhibitors at 11 teaching hospitals in Taiwan (2017-2021). Baseline characteristics, lipid-lowering therapies, and lipid profile changes were analyzed.

resultsAmong 211 patients (mean age 57.2 ± 13.1 years, 72.0% male), 73.5% used alirocumab and 26.5% used evolocumab. More than half had coronary artery disease and/or hypertension. Of these, 120 patients achieved the LDL-C target. Target achievers had a lower baseline BMI (25.8 ± 3.7 vs. 27.4 ± 4.5 kg/m

conclusionsLower BMI at baseline was associated with a higher likelihood of achieving LDL-C < 70 mg/dl after 12 weeks of PCSK9 inhibitor therapy. These findings support personalized strategies for optimizing cholesterol management in statin-intolerant patients while further investigations are required.

Indexed as

Anticholesteremic AgentsBody Mass IndexCholesterol, LDLHypercholesterolemiaPCSK9 InhibitorsAgedAntibodies, Monoclonal, HumanizedFemaleHumansMaleMiddle AgedProprotein Convertase 9Retrospective StudiesTaiwanalirocumabAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCholesterol, LDLevolocumabPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9BMILDL-C target achieverPCSK9 inhibitorStatin

Identifiers

PMID40089775
PMCPMC11909842

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.